HonorHealth Research Institute clinical trial, using non-surgical techniques, showed 86% of patients with a type of usually ...

Yang noted that SAVR and TAVR on their own just put valves in without any change in annular structure. Surgeons often turn ...

There is currently no way to stop calcification of the aortic valve. If all else fails, the valve must be replaced. To better ...

Aortic stenosis is a heart valve disease that some people don't realize they have. So what is it, how is it treated?

Edwards Lifesciences Corp.’s Sapien 3 platform has been approved for a new indication. The Food and Drug Administration recently cleared the line of catheter-based heart valves, which includes Sapien ...

Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for ...

Surgical bioprosthetic aortic valves made with bioengineered Resilia tissue (Edwards Lifesciences) appear to suffer less structural deterioration over 8 years compared with similar devices made of ...

In the study, which included 947 participants, 99.3% of patients in the Resilia arm saw no structural valve deterioration, versus 90.5% in the non-Resilia group.

CAIRO, April 18, 2025--Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue ...

The RESILIA tissue data from the trial reported encouraging results through eight years, with low rates of structural valve deterioration (99.3% freedom from SVD in the RESILIA tissue group versus ...

CAIRO, April 18, 2025--Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology ...